NEW YORK – AroCell today announced a collaboration and study with Boston-based Dana Faber Cancer Institute that aims to evaluate use of AroCell’s TK 210 ELISA, a quantitative immunoassay for the determination of thymidine kinase 1 (TK1) in human serum.
They will evaluate use of the assay to test samples from patients treated with palbociclib (Ibrance), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer.
One of the objectives of the study is to determine the concordance between TK1 concentration in serum and patients' clinical response to the treatment, Uppsala, Sweden-based AroCell said.
Increased levels in the blood of TK1 — an important enzyme in DNA precursor synthesis — can indicate active cell proliferation, the firm said.
It added that the TK 210 ELISA test provides information that can help clinicians to optimize treatment strategies and estimate the risk of a tumor recurring during disease monitoring.